Mastodon

Spongilan (Gel) Instructions for Use

ATC Code

D11AX (Other drugs used in dermatology)

Active Substance

Spongilla lacustris (Grouping name)

Clinical-Pharmacological Group

Drug of animal origin with local irritant, anti-inflammatory and analgesic action

Pharmacotherapeutic Group

Local irritant of plant origin

Pharmacological Action

A local irritant agent obtained from the freshwater sponge Spongilla, which represents colonies of coelenterate animals – Spongilla lacustris fragilis, Ephydatia fliviatilis.

The sponge lives only in exceptionally clean freshwater bodies with flowing water and at specific temperatures.

The skeleton of Spongilla consists of a looped network of silica needles bound together by an organic substance – spongin. It also includes phosphates, carbonates, and organic substances.

The action of Spongilla is based on the mechanical irritation of the skin due to the content of silicon needles.

Indications

Apply for the symptomatic relief of pain and inflammation associated with musculoskeletal conditions and minor injuries.

  • Radiculopathy and sciatica for nerve root pain management.
  • Arthritic conditions including rheumatoid arthritis and osteoarthritis.
  • Rheumatic disorders affecting soft tissues and joints.
  • Superficial injuries such as contusions, bruises, and hematomas.

ICD codes

ICD-10 code Indication
M05 Seropositive rheumatoid arthritis
M15 Polyosteoarthritis
M19.9 Unspecified arthrosis
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M79.0 Unspecified rheumatism
T14.0 Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect)
ICD-11 code Indication
8B93.Z Radiculopathy, unspecified
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
EH92 Dermatoses provoked by friction or mechanical impact
EH92.1 Blister due to friction
FA05 Polyosteoarthritis
FA0Z Osteoarthritis, unspecified
FA20.0 Seropositive rheumatoid arthritis
FA27.2 Palindromic rheumatism
FB51.3 Fibroblastic rheumatism
FB56 Specified soft tissue diseases, not elsewhere classified
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
ND56.0 Superficial injury of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply the gel externally to the affected skin areas two to three times daily.

Use a thin layer and gently massage into the skin until fully absorbed.

Avoid applying to large body surface areas simultaneously.

Discontinue use if severe skin irritation occurs and do not exceed the recommended application frequency.

Adverse Reactions

Local skin reactions are the most commonly reported adverse effects.

Expect transient skin hyperemia and a warming sensation due to the intended local irritant action.

Possible allergic contact dermatitis manifestations include pruritus, erythema, rash, or urticaria.

Discontinue use immediately if signs of a hypersensitivity reaction develop.

Drug Interactions

No specific drug interactions are currently documented.

Exercise caution when applying to the same area as other topical medications.

The local irritant effect may potentially enhance the percutaneous absorption of concurrently applied topical drugs.

Avoid simultaneous use with other topical irritants to prevent additive skin reactions.

Contraindications

Do not use under any circumstances if hypersensitivity to the active substance or any excipient is present.

  • Apply only to intact skin; avoid areas with cuts, abrasions, wounds, or any form of skin integrity impairment.
  • Do not use on skin conditions characterized by active inflammation, eczema, or dermatitis.
  • Avoid application to mucous membranes including the eyes, nose, and mouth.
  • Discontinue use if severe local reaction or systemic symptoms develop.

Overdose

Excessive application may intensify local adverse reactions including severe erythema, burning sensation, and skin irritation.

Treatment is symptomatic and supportive; immediately remove the product by washing the area thoroughly with water.

Do not apply occlusive dressings over the treated area as this may increase systemic absorption and skin reactions.

Seek medical attention if severe symptoms persist or if a significant amount has been ingested accidentally.

Special Precautions

Do not apply Spongilla to the mucous membrane of the nose and eyes; wash off Spongilla with water in case of contact.

To exclude the occurrence of an allergic reaction, it is recommended to apply a minimal amount of the Spongilla solution to the inner surface of the arm.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Skimed LLC (Russia)

Manufactured By

Reka-Pharm, CJS (Russia)

Dosage Form

Bottle OTC Icon Spongilan Gel for external use: tubes 30 g

Dosage Form, Packaging, and Composition

Gel for external use 1 tube
Spongilla lacustris (animal sponges of the Spongillidae family) 30 g

30 g – tubes (1) – cardboard packs.

Marketing Authorization Holder

Skimed LLC (Russia)

Manufactured By

Reka-Pharm, CJS (Russia)

Dosage Form

Bottle OTC Icon Spongilan Gel for external use: tubes 50 g

Dosage Form, Packaging, and Composition

Gel for external use 1 tube
Spongilla lacustris (animal sponges of the Spongillidae family) 50 g

50 g – tubes (1) – cardboard packs.

TABLE OF CONTENTS